155 related articles for article (PubMed ID: 38527521)
1. Regulation of energy metabolism through central GIPR signaling.
Liskiewicz A; Müller TD
Peptides; 2024 Jun; 176():171198. PubMed ID: 38527521
[TBL] [Abstract][Full Text] [Related]
2. Loss of GIPR in LEPR cells impairs glucose control by GIP and GIP:GLP-1 co-agonism without affecting body weight and food intake in mice.
Akindehin S; Liskiewicz A; Liskiewicz D; Bernecker M; Garcia-Caceres C; Drucker DJ; Finan B; Grandl G; Gutgesell R; Hofmann SM; Khalil A; Liu X; Cota P; Bakhti M; Czarnecki O; Bastidas-Ponce A; Lickert H; Kang L; Maity G; Novikoff A; Parlee S; Pathak E; Schriever SC; Sterr M; Ussar S; Zhang Q; DiMarchi R; Tschöp MH; Pfluger PT; Douros JD; Müller TD
Mol Metab; 2024 May; 83():101915. PubMed ID: 38492844
[TBL] [Abstract][Full Text] [Related]
3. Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism.
Mroz PA; Finan B; Gelfanov V; Yang B; Tschöp MH; DiMarchi RD; Perez-Tilve D
Mol Metab; 2019 Feb; 20():51-62. PubMed ID: 30578168
[TBL] [Abstract][Full Text] [Related]
4. Targeting the GIPR for obesity: To agonize or antagonize? Potential mechanisms.
Campbell JE
Mol Metab; 2021 Apr; 46():101139. PubMed ID: 33290902
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological characterization of mono-, dual- and tri-peptidic agonists at GIP and GLP-1 receptors.
Yuliantie E; Darbalaei S; Dai A; Zhao P; Yang D; Sexton PM; Wang MW; Wootten D
Biochem Pharmacol; 2020 Jul; 177():114001. PubMed ID: 32360365
[TBL] [Abstract][Full Text] [Related]
6. Human epicardial adipose tissue expresses glucose-dependent insulinotropic polypeptide, glucagon, and glucagon-like peptide-1 receptors as potential targets of pleiotropic therapies.
Malavazos AE; Iacobellis G; Dozio E; Basilico S; Di Vincenzo A; Dubini C; Menicanti L; Vianello E; Meregalli C; Ruocco C; Ragni M; Secchi F; Spagnolo P; Castelvecchio S; Morricone L; Buscemi S; Giordano A; Goldberger JJ; Carruba M; Cinti S; Corsi Romanelli MM; Nisoli E
Eur J Prev Cardiol; 2023 Jun; 30(8):680-693. PubMed ID: 36799940
[TBL] [Abstract][Full Text] [Related]
7. The GIP receptor displays higher basal activity than the GLP-1 receptor but does not recruit GRK2 or arrestin3 effectively.
Al-Sabah S; Al-Fulaij M; Shaaban G; Ahmed HA; Mann RJ; Donnelly D; Bünemann M; Krasel C
PLoS One; 2014; 9(9):e106890. PubMed ID: 25191754
[TBL] [Abstract][Full Text] [Related]
8. Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins'.
Skow MA; Bergmann NC; Knop FK
Diabetes Obes Metab; 2016 Sep; 18(9):847-54. PubMed ID: 27160961
[TBL] [Abstract][Full Text] [Related]
9. GIPR Function in the Central Nervous System: Implications and Novel Perspectives for GIP-Based Therapies in Treating Metabolic Disorders.
Samms RJ; Sloop KW; Gribble FM; Reimann F; Adriaenssens AE
Diabetes; 2021 Sep; 70(9):1938-1944. PubMed ID: 34176786
[TBL] [Abstract][Full Text] [Related]
10. GIP-derived GIP receptor antagonists - a review of their role in GIP receptor pharmacology.
Rosenkilde MM; Lindquist P; Kizilkaya HS; Gasbjerg LS
Peptides; 2024 Jul; 177():171212. PubMed ID: 38608836
[TBL] [Abstract][Full Text] [Related]
11. A Dual GLP-1/GIP Receptor Agonist Does Not Antagonize Glucagon at Its Receptor but May Act as a Biased Agonist at the GLP-1 Receptor.
Al-Zamel N; Al-Sabah S; Luqmani Y; Adi L; Chacko S; Schneider TD; Krasel C
Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31330984
[TBL] [Abstract][Full Text] [Related]
12. Discovery of a potent GIPR peptide antagonist that is effective in rodent and human systems.
Yang B; Gelfanov VM; El K; Chen A; Rohlfs R; DuBois B; Kruse Hansen AM; Perez-Tilve D; Knerr PJ; D'Alessio D; Campbell JE; Douros JD; Finan B
Mol Metab; 2022 Dec; 66():101638. PubMed ID: 36400403
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological Advances in Incretin-Based Polyagonism: What We Know and What We Don't.
Novikoff A; Müller TD
Physiology (Bethesda); 2024 May; 39(3):142-156. PubMed ID: 38353610
[TBL] [Abstract][Full Text] [Related]
14. Differential effects of glucose-dependent insulinotropic polypeptide receptor/glucagon-like peptide-1 receptor heteromerization on cell signaling when expressed in HEK-293 cells.
Al-Zaid B; Chacko S; Ezeamuzie CI; Bünemann M; Krasel C; Karimian T; Lanzerstorfer P; Al-Sabah S
Pharmacol Res Perspect; 2022 Oct; 10(5):e01013. PubMed ID: 36177761
[TBL] [Abstract][Full Text] [Related]
15. Glucose-dependent insulinotropic polypeptide regulates body weight and food intake via GABAergic neurons in mice.
Liskiewicz A; Khalil A; Liskiewicz D; Novikoff A; Grandl G; Maity-Kumar G; Gutgesell RM; Bakhti M; Bastidas-Ponce A; Czarnecki O; Makris K; Lickert H; Feuchtinger A; Tost M; Coupland C; Ständer L; Akindehin S; Prakash S; Abrar F; Castelino RL; He Y; Knerr PJ; Yang B; Hogendorf WFJ; Zhang S; Hofmann SM; Finan B; DiMarchi RD; Tschöp MH; Douros JD; Müller TD
Nat Metab; 2023 Dec; 5(12):2075-2085. PubMed ID: 37946085
[TBL] [Abstract][Full Text] [Related]
16. Immunomodulation and inflammation: Role of GLP-1R and GIPR expressing cells within the gut.
Morrow NM; Morissette A; Mulvihill EE
Peptides; 2024 Jun; 176():171200. PubMed ID: 38555054
[TBL] [Abstract][Full Text] [Related]
17. GLP-1 and GIP receptor signaling in beta cells - A review of receptor interactions and co-stimulation.
Mayendraraj A; Rosenkilde MM; Gasbjerg LS
Peptides; 2022 May; 151():170749. PubMed ID: 35065096
[TBL] [Abstract][Full Text] [Related]
18. The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling.
Zhang Q; Delessa CT; Augustin R; Bakhti M; Colldén G; Drucker DJ; Feuchtinger A; Caceres CG; Grandl G; Harger A; Herzig S; Hofmann S; Holleman CL; Jastroch M; Keipert S; Kleinert M; Knerr PJ; Kulaj K; Legutko B; Lickert H; Liu X; Luippold G; Lutter D; Malogajski E; Medina MT; Mowery SA; Blutke A; Perez-Tilve D; Salinno C; Sehrer L; DiMarchi RD; Tschöp MH; Stemmer K; Finan B; Wolfrum C; Müller TD
Cell Metab; 2021 Apr; 33(4):833-844.e5. PubMed ID: 33571454
[TBL] [Abstract][Full Text] [Related]
19. Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models.
Killion EA; Wang J; Yie J; Shi SD; Bates D; Min X; Komorowski R; Hager T; Deng L; Atangan L; Lu SC; Kurzeja RJM; Sivits G; Lin J; Chen Q; Wang Z; Thibault SA; Abbott CM; Meng T; Clavette B; Murawsky CM; Foltz IN; Rottman JB; Hale C; Véniant MM; Lloyd DJ
Sci Transl Med; 2018 Dec; 10(472):. PubMed ID: 30567927
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular biology of the GIP receptor.
Greenwell AA; Chahade JJ; Ussher JR
Peptides; 2020 Mar; 125():170228. PubMed ID: 31812593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
